Clinical Trial Update: Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on dasatinib combined with trastuzumab and paclitaxel in first-line HER2-positive metastatic breast cancer (Phase 1/2; completed; results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DASATINIB (Dasatinib)
• PACLITAXEL (PACLITAXEL)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Spanish Breast Cancer Research Group | Conditions: Metastatic Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-09-09